Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults

American Journal of Health-System Pharmacy

Volumn 56, Issue 22, 1999, Pages 2319-2324

  Carson, John J ^a  

^a St Peter's Hospital Albany   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LIPID; TICLOPIDINE;

ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; HEALTH CARE COST; HUMAN; LIPID BLOOD LEVEL; LOWEST INCOME GROUP; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SOCIOECONOMICS;

EID: 0033571005     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.22.2319     Document Type: Article

References (42)

1. Heart and stroke facts: 1996 statistical supplement. Dallas: American Heart Association, 1996; publication no. 55-0521.
2. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men. The NHANES I epidemiologic follow-up study. Ann Intern Med. 1997; 127:111-8.
3. Kraus JF, Borhani NO, Franti CE. Socioeconomic status, ethnicity and risk of coronary heart disease. Am J Epidemiol. 1980; 111:407-14.
4. Anderson KM, Wilson PWF, Odell PM et al. An updated coronary risk profile. Circulation. 1991; 83:356-62.
5. Ramsay LE, Haq IU, Jackson PR et al. Targeting lipid-lowering drug therapy for the primary prevention of coronary disease: an updated Sheffield table. Lancet. 1996; 348:387-8.
6. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994; 89:1329-445.
7. Antiplatelet Trialists' Collaboration. Collaborative overview of the randomised trials of antiplatelet therapy. BMJ. 1994; 308:81-106.
8. Manson JE, Tosteson H, Satterfield S et al. The primary prevention of myocardial infarction. N Engl J Med. 1992; 326: 1406-16.
9. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996; 335:453-61.
10. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N Engl J Med. 1991; 325:756-62.
11. Sullivan M, Vander Zwaag R, Hughes JP et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med. 1990; 150:2557-62.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
13. Sachs FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
14. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-7.
15. Frolkis JP, Zyzanski SJ, Schwartz JM et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 1998; 98:851-5.
16. Seto TB, Tremble MA, Ginsburg GS. Do we undertreat hyperlipidemia? The use of lipid-lowering agents in patients with coronary artery disease. J Am Coll Cardiol. 1996; 27(suppl A):304A. Abstract.
17. Salamone LM, Pressman AR, Seeley DG et al. Estrogen replacement therapy. A survey of older women's attitudes. Arch Intern Med. 1996; 156:1293-7.
18. Woolhandler S, Himmelstein DU. Reverse targeting of preventive care due to lack of health insurance. JAMA. 1988; 259:2872-4.
19. Donelan K, Blendon RJ, Hill CA et al. Whatever happened to the health insurance crisis in the United States? Voices from a national survey. JAMA. 1996; 276:1346-50.
20. Franks P, Clancy CM, Gold MR. Health insurance and mortality. Evidence from a national cohort. JAMA. 1993; 270:737-41.
21. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multi-disciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med. 1995; 155:2330-5.
22. Pauley TR, Magee MJ, Cury JD. Pharmacist-managed, physician-directed asthma management program reduces emergency department visits. Ann Pharmacother. 1995; 29:5-9.
23. Coast-Senior EA, Kroner BA, Kelley CL et al. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998; 32:636-41.
24. Wilt VM, Gums JG, Ahmed Ol et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995; 15:732-9.
25. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997; 17:140-7.
26. Census of the population, Albany County, NY, tract 26. Washington, DC: U.S. Bureau of the Census; 1990.
27. Smith SC, Blair SN, Criqui MH et al. Preventing heart attack and death in patients with coronary disease. J Am Coll Cardiol. 1995; 26:292-4.
28. Cairns JA, Lewis D, Meade TW et al. Antithrombotic agents in coronary artery disease. Chest. 1995; 108(suppl):380S-400S.
29. Grundy SM, Balady GJ, Criqui MH et al. Guide to the primary prevention of cardiovascular diseases: a statement for health-care professionals from the Task Force on Risk Reduction. Circulation. 1997; 95:2329-31.
30. Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995; 332:1125-31.
31. Healthy people 2000: national health promotion and disease prevention objectives. Washington, DC: U.S. Government Printing Office, 1991; publication no. 91-50212.
32. Solberg LI, Brekke ML, Kottke TE. Are physicians less likely to recommend preventive services to low-SES patients? Prev Med. 1997; 26:350-7.
33. Schrott HG, Bittner V, Vittingghoff E et al., for the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). JAMA. 1997; 277:1281-6.
34. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998; 280:605-13.
35. Kannel WB. Contributions of the Framingham study to the conquest of coronary artery disease. Am J Cardiol. 1988; 62:1109-12.
36. Wilson PWF, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97:1837-47.
37. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-9.
38. Kannel WB, Wolf PA, Castelli WP et al. Fibrinogen and the risk of cardiovascular disease: the Framingham study. JAMA. 1987; 258:1183-6.
39. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338:1042-50.
40. Harris-Hooker S, Sanford GL. Lipids, lipoproteins and coronary heart disease in minority populations. Atherosclerosis. 1994; 108(suppl):S83-104.
41. Pyorala K, De Backer G, Graham I et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994; 15:1300-31.
42. De Young M. Research on the effects of pharmacist-patient communication in institutions and ambulatory care sites, 1969-1994. Am J Health-Syst Pharm. 1996; 53:1277-91.